Page 96 - Contract Development News Today

PolyPeptide Group plans IPO and listing on the Swiss Stock Exchange EQS Group-News: PolyPeptide Group / Key word(s): IPO 12.04.2021 / 07:00 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON T...

Industry Movers: DSM, Chime, Danone & Evolva April 2021 and the COVID-19 saga continues to rumble on with news of an impending third wave throughout Europe. Despite plans to restrict movement, the rules don’t appear to have affected recruitment as NutraIngredients rounds up March’s movers and shakers. DSM has announced the retirement of Rob Routs as Chairman and member of the Board on 6 May 2021 as Thomas Leysen steps into the coveted role, held by routs for ten ...

AGC Biologics Appoints Jun Takami to General Manager/Site Head of Their Chiba, Japan Site Chiba, April 08, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Jun Takami as the General Manager/Site Head, to lead the continued successful operations as well as continuous improvements at its Chiba, Japan site. Mr. Takamis transition to the Site Head comes after a tremendously success...

AGC Biologics to Present Their End-to-End Cell and Gene Therapy Offering at ARMs Meeting on the Mediterranean Conference About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic pro...

Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia STOCKHOLM, April 1, 2021 /PRNewswire/ -- Today, Eurocine Vaccines AB ("Eurocine Vaccines") announces the completion of knowledge transfer and preparations for the development of the manufacturing process to secure the active protein needed in the toxicological and clinical studies with the companys chlamydia vaccine candidate and start of process development activities. "It is extremely satisfying to see...

Shares of Piramal Enterprises gained 3.3 per cent in the intra-day deals to quote at Rs 1,810 on the BSE on Thursday after the companys subsidiary, Piramal Pharma, acquired Hemmo Pharmaceuticals. "Piramal Pharma’s (PPL) Contract Development and Manufacturing Organization, Piramal Pharma Solutions (PPS), announced that PPL has entered into an agreement to acquire a 100 per cent stake in Hemmo Pharmaceuticals (Hemmo) for an upfront consideration of Rs 775 crore," Piramal Enterprises said in a p...

Eurofins Scientific: Make-whole Redemption Notice to the Bondholders Luxembourg and registered with the Register of Commerce and Companies of Luxembourg under number B 167.775) (the " Issuer Subject: Make-whole redemption notice to Bondholders of the EUR 500,000,000 2.25% senior notes due 27 January 2022 (ISIN Code: XS1174211471) with a nominal amount outstanding of EUR 279,233,000 (the " Notes We refer to the terms and conditions (the " Conditions") of the Notes issued by the Issuer on 27 Janu...

SK Holdings acquires French pharmaceutical company Yposkesi Photo by: SK/YouTube Related Stories SK Holdings revealed its acquisition of a French drug-maker called Yposkesi this week. The third-largest conglomerate in South Korea made the purchase in its bid to strengthen its competitive power in the global market’s biotech sector. Moreover, SK has acquired French drug manufacturer Yposkesi to expand into the rapidly growing contract manufacturing organization (CMO) business, the newly rena...

CET Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease asso CORK, Ireland, March 17, 2021 /PRNewswire/ -- Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in the United States and tested 2 ...

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction News provided by Share this article Share this article CORK, Ireland, March 17, 2021 /PRNewswire/ -- Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlle...